Apr 26, 2022 | Ad-hoc, CMC development, Featured news, News, Oligonucleotides
Strategic collaboration with Lilly to develop innovative and efficient processing solutions for the manufacture of oligonucleotide-based drug substances. The annual order volume has the potential to achieve around CHF 100 million, depending on Bachem reaching...
Feb 25, 2022 | CMC development, News, Oligonucleotides, Team
Capacity and sustainability are important unmet needs in oligonucleotide API manufacturing, that’s why providing solutions is key for the future. Find out in this interview with Seamus White, Business Development Manager at Bachem, how Bachem started the journey...
Oct 4, 2021 | CMC development, Knowledge, News, Peptides
A peptide is a chain of amino acids, which are used as building blocks. More commonly, peptides are short proteins with varying lengths from 2 amino acids to 100 amino acids. Peptides can be found in nature and can perform biological functions such as acting as...
Jul 20, 2021 | CMC development, Knowledge, News, Oligonucleotides
Our genetic information is stored in repeating sequence of nucleotides, abbreviated by the letters A, C, G, T in DNA, and A, C, G, U in RNA. DNA is a very large molecule that contains millions of nucleotides! Oligonucleotides are short single or double-stranded...
May 4, 2021 | CMC development, News, Peptides
We sat down with Robert Yu, CEO of Yuyu Pharma, to ask about his experience working with Bachem on a recent new chemical entity (NCE) project. Could you give us a short introduction to yourself and the company? My name is Robert Yu. I’m the CEO of Yuyu Pharma....
